1) Sipe JD, Cohen AS:Review:history of the amyloid fibril. J Struct Biol 130:88-98, 2000
2) Pras M, Schubert M, Zucker-Franklin D, et al:The characterization of soluble amyloid prepared in water. J Clin Invest 47:924-933, 1968
3) Glenner GG, Terry W, Harada M, et al:Amyloid fibril proteins:proof of homology with immunoglobulin light chains by sequence analyses. Science 172:1150-1151, 1971
4) Benditt EP, Eriksen N, Hermodson MA, et al:The major proteins of human and monkey amyloid substance:Common properties including unusual N-terminal amino acid sequences. FEBS Lett 19:169-173, 1971
5) Costa PP, Figueira AS, Bravo FR:Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA 75:4499-4503, 1978
6) Glenner GG, Wong CW:Alzheimer's disease:initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885-890, 1984
7) Westermark P, Benson MD, Buxbaum JN, et al:A primer of amyloid nomenclature. Amyloid 14:179-183, 2007
8) Kyle RA, Gertz MA:Primary systemic amyloidosis:clinical and laboratory features in 474 cases. Semin Hematol 32:45-59, 1995
9) Drayson M, Tang LX, Drew R, et al:Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97:2900-2902, 2001
10) Skinner M, Sanchorawala V, Seldin DC, et al:High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis:an 8-year study. Ann Intern Med 140:85-93, 2004
11) Kisilevsky R, Narindrasorasak S, Lee B, et al:During AA amyloidogenesis is proteolytic attack on serum amyloid A a pre- or post-fibrillogenic event? Amyloid 1:174-183, 1994
12) Wang S, Murphy CL, Kestler D, et al:SAA4-related AA amyloidosis. In:XIth International Symposium on Amyloidosis(Skinner M, Berk JL, Connors LH, et al eds), CRC Press, New York, pp105-107, 2007
13) Moriguchi M, Terai C, Kaneko H, et al:A novel single-nucleotide polymorphism at the 5'-flanking region of SAA1 associated with risk of type AA amyloidosis secondary to rheumatoid arthritis. Arthritis Rheum 44:1266-1272, 2001
14) Gillmore JD, Lovat LB, Persey MR, et al:Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358:24-29, 2001
15) Dember LM, Hawkins PN, Hazenberg BP, et al:Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 356:2349-2360, 2007
16) Ueda M, Ando Y, Nakamura M, et al:FK506 inhibits murine AA amyloidosis:possible involvement of T cells in amyloidogenesis. J Rheumatol 33:2260-2270, 2006
17) Ando Y, Nakamura M, Araki S:Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 62:1057-1062, 2005
18) Tojo K, Sekijima Y, Kelly JW, et al:Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res 56:441-449, 2006
19) Sato T, Ando Y, Susuki S, et al:Chromium(III)ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. FEBS Lett 580:491-496, 2006
20) Nakamura M, Ando Y, Nagahara S, et al:Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Ther 11:838-846, 2004
21) Terazaki H, Ando Y, Fernandes R, et al:Immunization in familial amyloidotic polyneuropathy:counteracting deposition by immunization with a Y78F TTR mutant. Lab Invest 86:23-31, 2006
22) Motomiya Y, Ando Y, Haraoka K, et al:Studies on unfolded beta-microglobulin at C-terminal in dialysis-related amyloidosis. Kidney Int 67:314-320, 2005
-microglobulin adsorption column on dialysis-related amyloidosis. Kidney Int 64:1522-1528, 2003
24) Hardy J, Selkoe DJ:The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics. Science 297:353-356, 2002
25) Andersson K, Olofsson A, Nielsen EH, et al:Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun 294:309-314, 2002